Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.05

-0.6%

Dec 9 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	2/10/2001 2:25:18 PM
From: blue_chip	Read Replies (1) of 52153

New Target for Oncolytics Thought you may be interested in more on this potential Oncolytic cancer treatment which may if it works be able to treat a great many types of cancers with potentially no side effects. Pfizer has already aquired the worldwide liscence for its use as a treatment to animals Here is some info from a recent research report "We consider Oncolytics Biotech (ONC:TSE) to be one of the most exciting investment opportunities in the Canadian biotechnology sector. Compelling research supports the contention that Oncolytics has identified, in the human reovirus, a novel and efficacious approach to cancer therapy. Broadly targeting the world cancer market, Oncolytics Biotech has the opportunity to capture substantial market share and benefit modern healthcare as well. The reovirus provides a novel and exciting approach to cancer therapy. Based on the reovirus’ cancer-cell killing activity, potent anti-cancer effects with minimal side effects have been described in numerous preclinical studies. We anticipate that the ongoing Phase I clinical trial will soon be complete, and that encouraging safety data will be reported. From a commercialization perspective, a number of factors point to Oncolytics’ potential for success. The recently signed veterinary deal with Pfizer, a possible listing on the NASDAQ and the expected corporate partnership for the human applications of reovirus all support the view that Oncolytics Biotech is poised for commercial success. The market opportunity for the pharmaceutical use of reovirus includes human and animal cancer. A review of the multi-billion dollar human and companion pet cancer markets reveals that reovirus is a potential blockbuster drug. Simple valuations demonstrate that if the human clinical trials are successfully completed, the upside for this company is significant. We have set our 12-month target price for the stock at $50." For more info see oncolyticsbiotech.com thenextwave.emerchantpro.com and for this whole research report see the recent report by lightyear technologies at the bottom of the page at thenextwave.emerchantpro.com Regards Chip

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next